晨化股份(300610.SZ):明年公司將力爭使非風電用產品的增量能夠彌補今年風電用產品的下滑量並有所增長
格隆匯12月18日丨晨化股份(300610.SZ)在投資者關係活動上表示,公司一直看好聚醚胺產品的發展前景,主要因為聚醚胺產品種類繁多,應用非常廣泛。儘管當前,風電用聚醚胺產品因風電行業整體需求疲軟,全年風機新增併網裝機量低於預期,加之國內同行業聚醚胺新增產能較多,導致國內競爭加劇,產品售價出現大幅下滑。明年公司將力爭使非風電用產品的增量能夠彌補今年風電用產品的下滑量並有所增長;當然更希望明年風電用聚醚胺產品的需求量出現較大反轉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.